Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 273 • 2014 ACR/ARHP Annual Meeting
Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis
Hermine Brunner¹, Nicola Ruperto², Carol A. Wallace³, Mary Toth⁴, Ivan Foeldvari⁵, John Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Pavla Vavrincova⁹, Daniel J. Kingsbury¹⁰, Katherine Marzan¹¹, Pierre Quartier¹², Kirsten Minden¹³, Elizabeth Chalom¹, Gerd Horneff¹⁴, Rolf M. Kuester¹⁵, Jason Dare¹⁶, Mareike Bereswill¹⁷, Hartmut Kupper¹⁷, Jasmina Kalabic¹⁷, Daniel Lovell¹⁸ and Alberto Martini¹⁹, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO, Genoa, Italy, ³University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ⁴Akron Children's Hospital, Akron, OH, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶University of Utah, Department of Pediatrics, Salt Lake City, UT, ⁷Pediatrics, Division of Pediatric Rheumatology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NC, ⁹Fakultni nemocnice v Motole, Praha, Czech Republic, ¹⁰Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹¹Children's Hospital Los Angeles, Los Angeles, CA, ¹²Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ¹³Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ¹⁵Asklepios Rheumazentrum Hamburg, Hamburg, Germany, ¹⁶Arkansas Children’s Hospital, Little Rock, AR, ¹⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁸Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ¹⁹PRINTO-IRCCS, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood. Adalimumab (ADA) is approved for moderate to severe polyarticular JIA…
Abstract Number: 2286 • 2014 ACR/ARHP Annual Meeting
Food Allergy and Celiac Disease in Children with Juvenile Idiopathic Arthritis
Trevor E. Davis^1,2, Mei-Sing Ong³, Diana Milojevic², Jyoti Ramakrishna⁴ and Marc D. Natter⁵, ¹Medicine, Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Pediatrics, Division of Pediatric Rheumatology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, ³Australian Institute of Health Innovation, University of New South Wales, Sydney, Australia, ⁴Pediatrics, Division of Pediatric Gastroenterology and Nutrition, Floating Hospital for Children at Tufts Medical Center, Boston, MA, ⁵Intelligent Health Labs, Children's Hospital Boston, Boston, MA
Background/Purpose: There are multiple strong associations between gut pathology and rheumatologic diseases. This connection, between primary GI disease and rheumatologic diseases, is manifest in both…
Abstract Number: 272 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from 2 UK Paediatric Biologic Registers
Rebecca Davies¹, Lianne Kearsley-Fleet¹, Eileen Baildam², Michael W. Beresford³, Helen E. Foster⁴, Taunton R. Southwood⁵, Wendy Thomson⁶, Kimme L. Hyrich⁷, on Behalf Of The BSPAR Etanercept Cohort Study¹ and The Biologics for Children with Rheumatic Diseases (BCRD) study¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ³Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁵Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁶Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologics such as etanercept (ETN), approved in the UK in…
Abstract Number: 2290 • 2014 ACR/ARHP Annual Meeting
Race and Other Risk Markers of Uveitis in a Prospective Cohort of Children with Juvenile Idiopathic Arthritis
Sheila T. Angeles-Han¹, Courtney McCracken¹, Steven Yeh², Kirsten Jenkins³, Erica Myoung⁴, Daneka Stryker⁴, Kelly A. Rouster-Stevens⁵, Larry B. Vogler¹, Christine Kennedy⁶, Sampath Prahalad¹ and Carolyn Drews-Botsch⁷, ¹Emory University School of Medicine, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory University, Atlanta, GA, ⁵Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁶Rheumatology Immunology, Emory Children's Center, Atlanta, GA, ⁷Epidemiology, Emory University School of Public Health, Atlanta, GA
Background/Purpose Juvenile idiopathic arthritis-associated uveitis (JIA-U) can lead to poor visual outcomes. American Academy of Pediatric guidelines recommend screening every 3 months in children with…
Abstract Number: 271 • 2014 ACR/ARHP Annual Meeting
Predicting Treatment Response to Etanercept in Juvenile Idiopathic Arthritis: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN)
Lianne Kearsley-Fleet¹, Rebecca Davies¹, Mark Lunt¹, Taunton R. Southwood², Kimme L. Hyrich³ and on Behalf Of The BSPAR Etanercept Cohort Study¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Etanercept (ETN) is licensed in Europe for use in children with Juvenile Idiopathic Arthritis (JIA) and is routinely prescribed after failure of other DMARDs.…
Abstract Number: 1866 • 2014 ACR/ARHP Annual Meeting
Birth Outcomes in Women with a History of Juvenile Idiopathic Arthritis
Debbie Ehrmann Feldman¹, Evelyne Vinet², Sasha Bernatsky³, Ciaran Duffy⁴, Elizabeth Hazel⁵, Marie-Pierre Sylvestre⁶, Garbis Meshefedjian⁷ and Anick Bérard¹, ¹Université de Montréal, Montréal, QC, Canada, ²McGill University Health Center, Montreal, QC, Canada, ³Clinical Epidemiology - Rheumatology, McGill University, Montreal, QC, Canada, ⁴Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁵McGill University Heatlh Center, Montreal, QC, Canada, ⁶médecine sociale et préventive, Université de Montréal, Montréal, QC, Canada, ⁷Public Health Department of Montreal, Montreal, QC, Canada
Background/Purpose: Although there is a higher frequency of adverse birth outcomes in women with rheumatoid arthritis, little is known on the subject regarding women who…
Abstract Number: 276 • 2014 ACR/ARHP Annual Meeting
Growth during Tocilizumab Therapy for Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial
Kamal N. Bharucha¹, Hermine I. Brunner², Nicola Ruperto³, David A. Cabral², Abraham Gedalia², Valeria Gerloni³, Christian Jorgensen³, Athimalaipet Ramanan³, Daniel Lovell², Alberto Martini⁴, James Frane⁵, Chris Wells⁶ and Fabrizio De Benedetti Sr.⁷, ¹Genentech, South San Francisco, CA, ²PRCSG, Cincinnati, OH, ³PRINTO, Genoa, Italy, ⁴Istituto Giannina Gaslini, Genova, Italy, ⁵Consultant, Santa Monica, CA, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy
Background/Purpose: Elevated interleukin-6 (IL-6) levels have been associated with low growth velocity in patients with juvenile idiopathic arthritis (JIA).1 The efficacy of tocilizumab (TCZ), an…
Abstract Number: 1444 • 2014 ACR/ARHP Annual Meeting
The Vocational Experiences of Young People with Juvenile Idiopathic Arthritis and the Role of the Multidisciplinary Team Supporting Positive Employment Outcomes
Helen Hanson¹, Ruth Hart², Alison Jordan³, Rachel Tattersall⁴, Ben Thompson¹ and Helen E. Foster⁵, ¹Rheumatology, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁴Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, ⁵Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Recent decades have seen marked changes in the management of juvenile idiopathic arthritis (JIA), with improved clinical outcomes for many patients. However, unemployment rates…
Abstract Number: 198 • 2014 ACR/ARHP Annual Meeting
Implant Survival and Patient-Reported Outcomes after Total Hip Arthroplasty in Young Patients with JIA
Ishaan Swarup¹, Ella Christoph¹, Lisa A. Mandl², Susan M. Goodman² and Mark P. Figgie³, ¹Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Orthopedics, Hospital for Special Surgery, New York, NY
Background/Purpose : Juvenile Idiopathic Arthritis (JIA) is a common rheumatologic disease in children that often persists into adulthood. The hip joint is commonly involved, and…
Abstract Number: 1313 • 2014 ACR/ARHP Annual Meeting
Comorbidity Patterns in Children with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance Registry
Marc D. Natter¹, Mei-Sing Ong², Kenneth D. Mandl³, Laura Schanberg⁴, Yukiko Kimura⁵, Norman Ilowite⁶ and the CARRA Registry Investigators, ¹Intelligent Health Labs, Children's Hospital Boston, Boston, MA, ²Australian Institute of Health Innovation, University of New South Wales, Sydney, Australia, ³Intelligent Health Lab, Children's Hospital Boston, Boston, MA, ⁴Duke University, Durham, NC, ⁵Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁶Rheumatology, Children's Hospital Montefiore, Bronx, NY
Background/Purpose: Knowledge of co-occurring disease processes (comorbidities) is important for understanding disease pathogenesis, refining disease classifications, developing appropriate screening and prevention strategies, and determining overall…
Abstract Number: L2 • 2014 ACR/ARHP Annual Meeting
A Comparison of Three Treatment Strategies in Recent Onset DMARD Naïve Juvenile Idiopathic Arthritis: 3-Months Results of the BeSt for Kids-Study
Petra C.E. Hissink Muller^1,2, D.M.C. Brinkman^1,3, Dieneke Schonenberg⁴, Yvonne Koopman-Keemink⁵, J. Merlijn Van den Berg⁶, W.P. Bekkering⁷, Marion van Rossum^8,9, Lisette WA van Suijlekom-Smit¹⁰, Cornelia F. Allaart¹¹ and Rebecca ten Cate¹, ¹Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Pediatric Rheumatology, Reade, Amsterdam, Netherlands, ³Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, ⁴Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁵Pediatrics, Haga ziekenhuis, The Hague, Netherlands, ⁶Pediatric Hematology, Immunology and Infectious diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁷Pediatric Physiotherapy, Leiden University Medical Center, Leiden, Netherlands, ⁸Pediatric Rheumatology Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁹Reade, Amsterdam, Netherlands, ¹⁰Pediatric Rheumatology, Sophia Children's Hospital Erasmus Medical Center, Rotterdam, Netherlands, ¹¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: BeSt for Kids compares 3 Disease Modifying Anti Rheumatic Drug (DMARD) strategies in juvenile idiopathic arthritis (JIA) patients, for time to inactive disease, time…
Abstract Number: 928 • 2014 ACR/ARHP Annual Meeting
A Multinational Study of the Epidemiology, Treatment and Outcome of Childhood Arthritis: Preliminary Data from 6,940 Patients
Alessandro Consolaro¹, Amita Aggarwal², Troels Herlin³, Olga Vougiouka⁴, Rubén Burgos-Vargas⁵, Ilonka Orban⁶, Nahid Shafaie⁷, Maria Trachana⁸, Lidia Rutkowska-Sak⁹, Ingrida Rumba-Rozenfelde¹⁰, Dimitrina Mihaylova¹¹, Alberto Martini^12,13 and Angelo Ravelli^1,14, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴P. A. Kyriakou Childrens Hospital of Athens University, Athens, Greece, ⁵Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁷Rheumatology Research Centre, Tehran University of Medical Sciences, Tehran, Iran, ⁸Aristotle University, Thessaloniki, Greece, ⁹Institute of Rheumatology, Warsaw, Poland, ¹⁰University of Latvia, Riga, Latvia, ¹¹University Children Hospital, Sofia, Bulgaria, ¹²Istituto Giannina Gaslini, Genova, Italy, ¹³University of Genova, Genova, Italy, ¹⁴Istituto Giannina Gaslini and University of Genova, Genova, Italy
Background/Purpose The epidemiology of juvenile idiopathic arthritis (JIA) is known to be variable worldwide and the therapeutic approach to JIA is not standardized. Moreover, the…
Abstract Number: 303 • 2014 ACR/ARHP Annual Meeting
Predicting Chronic Pain in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Prospective Study
Amir Rashid¹, Kate Holliday¹, Lis Cordingley¹, Roberto Carrasco¹, Bo Fu², Helen E. Foster³, Eileen Baildam⁴, Alice Chieng⁵, Joyce Davidson⁶, Lucy Wedderburn⁷, Kimme Hyrich⁸ and Wendy Thomson⁹, ¹Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ²Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester, United Kingdom, ³Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁵Paediatric Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁶Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁷Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ⁸Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁹Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom
· Background/Purpose: Pain is the most common symptom of JIA and has been associated with disease activity. However, disease activity has only accounted for a…
Abstract Number: 302 • 2014 ACR/ARHP Annual Meeting
Qualitative Assessment of Important Long-Term Outcomes in Juvenile Idiopathic Arthritis
Melissa L. Mannion¹, Michelle Williams², Gerald McGwin Jr.³, Kenneth G. Saag⁴ and Timothy Beukelman¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose JIA is not a childhood disease, but a chronic disease that begins in childhood. Long term outcomes that physicians and patients care most about…
Abstract Number: 301 • 2014 ACR/ARHP Annual Meeting
Pregnancies in Females with Juvenile Idiopathic Arthritis (JIA) Who Were Exposed to Biologics and/or Methotrexate – Results from a Biologic Register
Katrin Stüdemann¹, Martina Niewerth¹, Jens Klotsche¹, Angela Zink², Gerd Horneff³ and Kirsten Minden^1,4, ¹Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ³Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Chidlrens´ hospital, Charité University Medicine, Berlin, Germany
Background/Purpose JIA often continues into adult life and affects about 1 in 1,000 people of childbearing age. Little is known about the impact of JIA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].